Conversion to Full Donor Chimerism Following Donor Lymphocyte Infusion Is Associated with Disease Response in Patients with Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 4, 2000, Pages 375-386

  Orsini, Enrica ^b   Alyea, Edwin P ^b   Chillemi, Antoinette ^b   Schlossman, Robert ^b   McLaughlin, Stephen ^b   Canning, Christine ^b   Soiffer, Robert J ^b   Anderson, Kenneth C ^b   Ritz, Jerome ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Bone marrow transplantation; Chimerism; Donor lymphocyte infusion; Multiple myeloma; T cell repertoire

Indexed keywords

LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL; ARTICLE; BLOOD; BLOOD DONOR; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE TRANSFUSION; LYMPHOCYTOSIS; MULTIPLE MYELOMA; RECURRENT DISEASE; TIME;

ANIMALS; ANTIGENS, CD; BLOOD DONORS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIESIS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE TRANSFUSION; LYMPHOCYTOSIS; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECURRENCE; TIME FACTORS; TRANSPLANTATION CHIMERA;

EID: 0033642858     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70014-0     Document Type: Article

References (33)

1. Kolb HJ, Mittermuller J, Clem C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
2. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
3. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995; 86:2041-2050.
4. Porter D, Collins R, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999;5:253-261.
5. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196-1198.
6. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia. 1997;11:281-283.
7. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet. 1996;347:800-801.
8. Lokhorst H, Schattenberg A, Cornelissen J, Thomas L, Verdonck L. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.
9. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998; 91:3671-3680.
10. Keil F, Haas O, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood. 1997;89: 3113-3117.
11. Rapanotti MC, Arcese W, Buffolino S, et al. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. Bone Marrow Transplant. 1997; 19:703-707.
12. Verdonck L, van Blokland W, Bosboom-Kalsbeek E, et al. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells. Bone Marrow Transplant. 1996;18:389-395.
13. Baurmann H, Nagel S, Binder T, et al. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood. 1998;92:3582-3590.
14. Gardiner N, Lawler M, O'Riordan J, et al. Monitoring of lineage-specific chimerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeioid leukaemia. Bone Marrow Transplant. 1998;21:711-719.
15. + minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest. 1995;96:877-883.
16. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91:2197-2207.
17. Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999;5:839-842.
18. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336-2341.
19. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992;10:1191-1200.
20. Soiffer R, Fairclough D, Robertson M, et al. CD6 depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997;89:3039-3047.
21. Oberkircher AR, Strout MP, Herzig GP, Fritz PD, Caligiuri MA. Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;16:695-702.
22. Claret E, Alyea E, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia following donor lymphocyte infusion. J Clin Invest. 1997;100:855-866.
23. Orsini E, Alyea E, Schlossman R, et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma receiving donor lymphocyte infusion. Bone Marrow Transplant. 2000;25:623-632.
24. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000;95:352-359.
25. Pannetier C, Cochet M, Darche S, et al. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA. 1993;90:4319-4323.
26. Gorski J, Yassai M, Zhu X, et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping: correlation with immune status. J Immunol. 1994;152:5109-5119.
27. Bosserman LD, Murray C, Takvorian T, et al. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989;4:239-245.
28. Economou J, Belldegrun A, Glaspy J, et al. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. J Clin Invest. 1996;97:S15-S21.
29. Jacob J, Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature. 1999;399:593-597.
30. Battaglia M, Andreani M, Manna M, et al. Coexistence of two functioning T-cell repertoires in healthy ex-thalassemics bearing a persistent mixed chimerism years after bone marrow transplantation. Blood. 1999;94:3432-3438.
31. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995; 86:4337-4343.
32. Hicklin D, Wang Z, Arienti F, et al. Beta2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998;101:2720-2729.
33. Lee P, Yee C, Savage P, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.